| 7 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.75 | 1-year : | 38.61 |
| Resists | First : | 32.32 | Second : | 33.06 |
| Pivot price | 31.88  |
|||
| Supports | First : | 31.13 | Second : | 25.9 |
| MAs | MA(5) : | 31.6 |
MA(20) : | 32.05 |
| MA(100) : | 32.11 |
MA(250) : | 32.52 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 24.1 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 35.72 | Low : | 30.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LTC ] has closed above bottom band by 33.3%. Bollinger Bands are 4.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.66 - 31.92 | 31.92 - 32.1 |
| Low: | 30.74 - 31.03 | 31.03 - 31.22 |
| Close: | 30.94 - 31.38 | 31.38 - 31.68 |
Mon, 31 Oct 2022
Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight - GlobeNewswire
Mon, 13 Jun 2022
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis ... - PR Newswire
Mon, 13 Jun 2022
TLC Announces TLC599 Agreement with Endo - Yahoo Finance
Wed, 08 Sep 2021
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares - Yahoo Finance
Mon, 05 Jul 2021
TLC Announces Details of Stock Swap Transactions - GlobeNewswire
Wed, 14 Oct 2020
TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 73 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | 2.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.48 |
| Profit Margin | 46.7 % |
| Operating Margin | 53.1 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 10.3 % |
| Qtrly Rev. Growth | 4.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.44 |
| EBITDA (p.s.) | 3.42 |
| Qtrly Earnings Growth | 53.5 % |
| Operating Cash Flow | 104 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | 14.62 |
| PEG Ratio | -2.1 |
| Price to Book value | 1.54 |
| Price to Sales | 7.09 |
| Price to Cash Flow | 13.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|